Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
Obesity is a heightened state of inflammation in which production of cytokines and matrix
metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin
resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance
insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes
(DM2).
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Diego
Collaborators:
National Center for Research Resources (NCRR) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Ruth L. Kirschstein National Research Service Award